The results of the pooling analysis (Figure 5) further affirmed that FASN expression was higher in bladder cancer, colorectal cancer, lymphoma, ovarian cancer, and prostate cancer tissues (P < 0.001) than in corresponding normal controls. This evidence concerns the gene FASN and urinary bladder cancer.